{
    "Trade/Device Name(s)": [
        "Elecsys proBNP II",
        "Elecsys proBNP II STAT"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K210546",
    "Predicate Device Reference 510(k) Number(s)": [
        "K072437",
        "K092649"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBC"
    ],
    "Summary Letter Date": "December 8, 2021",
    "Summary Letter Received Date": "December 8, 2021",
    "Submission Date": "March 28, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1117"
    ],
    "Regulation Name(s)": [
        "B-Type Natriuretic Peptide Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "N-terminal pro-Brain natriuretic peptide (NT-proBNP)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Serum tube",
        "Lithium heparin tube",
        "K2-EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "cobas e 411 analyzer",
        "cobas e 601 analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemiluminescence immunoassay (ECLIA)",
        "Sandwich immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Quantitative analysis"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Roche Elecsys proBNP II and Elecsys proBNP II STAT immunoassays for NT-proBNP using ECLIA technology on cobas e analyzers with improved biotin tolerance.",
    "Indications for Use Summary": "Immunoassays for in vitro quantitative determination of NT-proBNP in human serum and plasma to aid diagnosis of suspected heart failure, risk stratification in acute coronary syndrome and heart failure, and assessment of cardiovascular risk in stable coronary artery disease patients.",
    "fda_folder": "Clinical Chemistry"
}